about
Terminal vessel hyperperfusion despite organ hypoperfusion in familial dysautonomia.The role of quantitative structural imaging in the early diagnosis of Alzheimer's disease.Early detection of Alzheimer's disease using neuroimaging.Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease.Hippocampal blood flow in normal aging measured with arterial spin labeling at 3TFramingham cardiovascular risk profile correlates with impaired hippocampal and cortical vasoreactivity to hypercapniaTMS enhances retention of a motor skill in Parkinson's disease.Effects of memantine on cerebrospinal fluid biomarkers of neurofibrillary pathology.Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolismHypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaintsRobust and conventional neuropsychological norms: diagnosis and prediction of age-related cognitive decline.Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer diseaseInflammation and Alzheimer's disease: possible role of periodontal diseases.An entorhinal cortex sulcal pattern is associated with Alzheimer's disease.Magnetic resonance imaging improves cerebrospinal fluid biomarkers in the early detection of Alzheimer's disease.Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment.The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease.TNF-alpha and antibodies to periodontal bacteria discriminate between Alzheimer's disease patients and normal subjects.Multifocal repetitive TMS for motor and mood symptoms of Parkinson disease: A randomized trial.Freezing of gait in Parkinson's disease: from pathophysiology to emerging therapies.Subjective memory complaints: presence, severity and future outcome in normal older subjects.Small fiber dysfunction predominates in Fabry neuropathy.Clonidine improves postprandial baroreflex control in familial dysautonomia.Cognitive performance in mid-stage Parkinson's disease: functional connectivity under chronic antiparkinson treatment.Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease.Longitudinal CSF isoprostane and MRI atrophy in the progression to AD.Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054Orthostatic challenge reveals impaired vascular resistance control, but normal venous pooling and capillary filtration in familial dysautonomia[Vascular abnormalities in patients with primary intracerebral hemorrhage]Enzyme replacement therapy improves cardiovascular responses to orthostatic challenge in Fabry patientsCardiac responses to orthostatic stress deteriorate in Parkinson disease patients who begin to fallMetronomic breathing shows altered parasympathetic baroreflex function in untreated Fabry patients and baroreflex improvement after enzyme replacement therapyTossing and Turning in Bed: Nocturnal Movements in Parkinson's Disease
P50
Q30923180-D449F44D-ABCB-41AD-8F15-EE0A79BE0A89Q31030916-A08AB375-40D0-4C25-81B0-6C581465CF8AQ31048702-8E2C293C-2AE2-4FA7-8465-CA25F11556D7Q31108280-4070F792-BA25-4B94-AB7C-1D758B93B8E0Q34495628-8AD658FA-5272-42DC-BFD4-2C4BF2442A74Q34627635-54D65324-CA38-401D-9C8C-83172A290AB9Q35039637-CC696296-5EFE-4F30-8B75-715D3CC474B7Q35067938-DAD8D0CA-F060-4ECD-BCF5-E37CBBB8CD22Q36277213-FFA7A496-29EC-4348-BA25-540E5570D9C7Q36661066-D574AEDE-0940-4F67-A9D1-05BF51154CD2Q37141212-4DD4B244-45BA-42AC-ABC7-7FB37ABEE598Q37180524-9AF512B6-DE10-4E77-B9F5-DC62D1980F53Q37218226-D3D8ADB8-335C-4DB9-8F0B-BED3D6553FF2Q37219729-29283031-FE8D-483D-BFA3-72AC8B2B5CBDQ37369308-A721CE13-2D8B-49EB-AD9A-A2E73A1A0B39Q37415283-6447992E-FF28-4F55-B292-C267BA95AF38Q37415302-383B2FA4-03B5-44DA-8609-6D041AC2288AQ37440824-4B79E026-4296-4CE3-BE2E-6228D4E56D2EQ38385451-1C2C9040-E380-494D-AF8B-3544F32DA1FCQ38947418-B4098D30-7858-4F1E-9BDE-E2501BDB38D6Q40191414-F970B6F3-B2A9-41CB-90D8-C8E5A207283DQ44253720-E260C488-CAD0-4765-99D1-CFB7E45824B8Q44597496-B3BE77B3-849C-4A2E-BA44-DBB58D630FA9Q47932921-81D6C079-3272-4464-B87B-581F56DC4201Q47977280-E6EC0A08-3F0E-4562-BB72-C7BD7A0C5DE4Q51969903-CFCF2318-2FBE-4664-962B-2654E3C4BF3AQ64760145-F276D614-FF51-41DE-9625-D5B472A79A23Q78839575-50970C75-E859-4351-81EF-5858BCC36D63Q80174710-976C1EEA-74B0-4007-B968-98A30EBF3B3DQ82748091-0D0AB224-9FCF-4E01-BCA9-092D6D556970Q85003761-0C9AC209-3AD8-4749-91B5-8C8E92C1C378Q85040262-EF8A9913-1187-4B86-B0EC-E7218F0C4D08Q89813868-F384EC4F-4D84-49E8-A7C8-59B53643FFE4
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Miroslaw Brys
@ast
Miroslaw Brys
@en
Miroslaw Brys
@es
Miroslaw Brys
@nl
type
label
Miroslaw Brys
@ast
Miroslaw Brys
@en
Miroslaw Brys
@es
Miroslaw Brys
@nl
prefLabel
Miroslaw Brys
@ast
Miroslaw Brys
@en
Miroslaw Brys
@es
Miroslaw Brys
@nl
P106
P31
P496
0000-0003-3682-117X